THE MAVIS NYE FOUNDATION
Registered charity 1172765 in England & Wales.
In brief: THE MAVIS NYE FOUNDATION ranks 70,889 of 153,220 registered charities in England and Wales with accounts on file, by latest income. In its latest year it spent more than it received: spending was 119% of income.
- THE MAVIS NYE FOUNDATION is registered charity 1172765 in England and Wales, registered on 25 Apr 2017.
- What it does: To offer grants to enable clinical research into producing new drugs to fight Mesothelioma.
- Money: latest income £31k, latest spending £37k (financial year ending 30 Apr 2023).
- Status: registered, with no insolvency or administration flag.
Source: Charity Commission for England and Wales register. Updated .
Is THE MAVIS NYE FOUNDATION a registered charity?
Yes. THE MAVIS NYE FOUNDATION is registered with the Charity Commission for England and Wales as charity number 1172765, registered on 25 Apr 2017.
Is THE MAVIS NYE FOUNDATION insolvent or in administration?
This charity is registered with no insolvency or administration flag on the Charity Commission register (as of 20 Nov 2026). This reflects the register only. It is not an endorsement or a guarantee, and it does not cover concerns the register would not record.
What does THE MAVIS NYE FOUNDATION do?
In its own words on the register: "To offer grants to enable clinical research into producing new drugs to fight Mesothelioma."
How much money does THE MAVIS NYE FOUNDATION receive and spend?
Its latest income on the register is £31k and its latest spending is £37k, for the financial year ending 30 Apr 2023.
Where can I check the official record?
- Charity Commission record for 1172765 ↗ (the official, current source).
- Source: Charity Commission for England and Wales, synced from the corefi warehouse. As of 20 Nov 2026.
Get new data by email
A short email when we publish new data or analysis on UK public money, about once a month. Unsubscribe at any time.
We use your email only to send this newsletter and you must confirm it first. See our privacy policy.